The ASPREE clinical trial
cancer, cardiovascular disease
CANCER, SECONDARY, CARDIOVASCULAR DISEASE
This ASPREE trial was a secondary, intention-to-treat analysis of ASPREE clinical trial data (ClinicalTrials.gov ID NCT01038583). The ASPREE study enrolled community-dwelling individuals 70 years of age or older (≥65 years of age for members of US minority groups) with no major cardiovascular disease in Australia and the United States. Preexisting cancer was not an exclusion if life expectancy was beyond 5 years [19% of participants had preexisting cancer (